Market Overview

UPDATE: Bernstein Downgrades Merck & Co. on Negative Outlook

Share:
Related MRK
New Analyses from the IMPROVE-IT Outcomes Study of VYTORIN and the TECOS Cardiovascular Safety Trial of JANUVIA Will Be Presented at the European Society of Cardiology Congress
FDA Accepts Supplemental Biologics License Application for KEYTRUDA, Merck's Anti-PD-1 Therapy, for First-Line Treatment of Advanced Melanoma, and Grants Priority Review
Novo Nordisk to Start PIONEER Program on Semaglutide (Zacks)

In a report published Monday, Bernstein Research analyst Tim Anderson downgraded the rating on Merck & Co. (NYSE: MRK) from Outperform to Market Perform, and lowered the price target from $53.00 to $50.00.

In the report, Bernstein Research noted, “We are downgrading Merck to Market-Perform from Outperform. From a pure financial perspective, 2013 is not likely going to be a great year - revenues and EPS should be down vs 2012 as prior generic expiries continue to wash through the model. Furthermore, following a string of pipeline setbacks and now the lowering of 2013 guidance twice since the start of the year, a ‘crisis in confidence' among investors has been building. While expectations and valuation are now lower, many investors continue to view MRK as a good R&D company because of its historic good legacy (this has been part of our original investment case too). Accordingly, pipeline execution will be critical to the story, but in the nearer-term it is hard to identify many meaningful pipeline catalysts.”

Merck & Co. closed on Friday at $47.29.

Latest Ratings for MRK

DateFirmActionFromTo
Aug 2015JefferiesMaintainsHold
Aug 2015BMO CapitalUpgradesMarket PerformOutperform
Jun 2015Piper JaffrayInitiates Coverage onNeutral

View More Analyst Ratings for MRK
View the Latest Analyst Ratings

Posted-In: Bernstein Research Tim AndersonAnalyst Color Downgrades Analyst Ratings

 

Related Articles (MRK)

Get Benzinga's Newsletters